Vascular News and Research

RSS

Distribution agreement signed between Cardiovascular Systems and Asahi Intecc

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has signed an exclusive distribution agreement with Asahi Intecc Co., Ltd., based in Japan, to market its peripheral guide wire line in the United States.

28 Aug 2009

Studies suggest that venous ischemia causes greater injury than arterial ischemia

The research team led by Professor Guzman-de la Garza of the Autonomous University of Nuevo Leon, Mexico, used a rodent model of intestinal I/R to study the different inflammatory mediators that are associated with venous, arterial or total vascular occlusion.

27 Aug 2009

Polycystic ovary syndrome in women can be relieved by acupuncture and exercise

Polycystic ovary syndrome, a common condition among women, can be relieved by the use of acupuncture and exercise. This has been shown by a recent study at the Sahlgrenska Academy, University of Gothenburg, Sweden.

27 Aug 2009

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.

27 Aug 2009

Initial abstract for the clinical study of PLC's RenalGuard System published

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that the initial abstract for the investigator-sponsored clinical study of its RenalGuard System(TM) has been published, in advance of the annual meeting of the European Society of Cardiology, August 29 - September 2, 2009 in Barcelona, Spain, on the ESC website.

26 Aug 2009

New online educational forum for medical professionals from HMP Communications

HMP Communications, the authoritative source for education services targeting healthcare professionals for over two decades, announced it has added a new online educational forum at www.CardiovascularLIVE.com. The site offers video instruction and discussion forums for medical professionals.

26 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

GE Healthcare and TomTec Imaging Systems collaborate to streamline cardiologist’s workflows

GE Healthcare, a division of General Electric Company and TomTec Imaging Systems GmbH, a worldwide leader in 2D/3D/4D imaging and quantification technologies, have entered into a formal strategic cooperation contract to boost their excellence in echocardiography.

25 Aug 2009

First patient enrolled for IDEV Technologies' SUPERB clinical trial

IDEV(R) Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that the first patient was enrolled in the Company's FDA-approved multi-center clinical trial of its self-expanding SUPERA(R) stent, a novel stent platform designed for the treatment of biliary and peripheral artery disease (PAD) in the superficial femoral artery (SFA).

25 Aug 2009

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

Mild glucose intolerance in pregnancy may be an early identifier of women who are at increased risk of heart disease in the future, found a new study http://www.cmaj.ca/press/cmaj090569.pdf published in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

25 Aug 2009

Low-carbohydrate and high-protein diet increases the risk for atherosclerosis and impaired blood vessels

Even as low-carbohydrate/high-protein diets have proven successful at helping individuals rapidly lose weight, little is known about the diets' long-term effects on vascular health.

25 Aug 2009

Thick blood to cause or prevent strokes and heart attacks proved by scientists

"Thick" blood can cause heart attack and stroke, but also prevent them. Scientists at Heidelberg University Hospital have explained the mechanism of this clinical paradox for the first time on an animal model. Mice with a greater tendency to form blood clots have larger plaques in their vessels, but they are more stable.

24 Aug 2009

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalised medication is increasingly common.

24 Aug 2009

Endologix publishes abdominal aortic aneurysm treatment trial results online

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today the online publication of results from the pivotal prospective, multicenter clinical trial of the Company's Powerlink XL((R)) System for treatment of abdominal aortic aneurysm in large diameter proximal aortic necks.

21 Aug 2009

Kensey Nash announces financial results for fourth-quarter and full fiscal year 2009

Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its fourth quarter and fiscal year ended June 30, 2009.

20 Aug 2009

Massachusetts General Hospital selects BDV's video and audio solution for improving operating room efficiency

Black Diamond Video, Inc. (BDV) announces that Massachusetts General Hospital has selected BDV to integrate their state-of-the-art Integrated Digital Surgical Suites (IDSS) video and audio solution into their new operating rooms and vascular hybrid suites. The IDSS will enhance the quality and efficiency of care delivered by the Massachusetts General Hospital’s surgical, nursing, radiology, pathology and clinical engineering teams by providing high-resolution video routing, audio routing, multi-windowing, printing, recording and video streaming.

20 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

Researcher of LA BioMed elected to distinguished fellow status of SVS

Carlos E. Donayre, MD, a researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), has been elected to distinguished fellow status of the Society for Vascular Surgery- (SVS).

20 Aug 2009

Cardiovascular Systems' revenues in fourth-quarter of 2009 increases to $15.7 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fourth quarter and fiscal year ended June 30, 2009.

19 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Vascular News and Research

Distribution agreement signed between Cardiovascular Systems and Asahi Intecc

Studies suggest that venous ischemia causes greater injury than arterial ischemia

Polycystic ovary syndrome in women can be relieved by acupuncture and exercise

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

Initial abstract for the clinical study of PLC's RenalGuard System published

New online educational forum for medical professionals from HMP Communications

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

GE Healthcare and TomTec Imaging Systems collaborate to streamline cardiologist’s workflows

First patient enrolled for IDEV Technologies' SUPERB clinical trial

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

Low-carbohydrate and high-protein diet increases the risk for atherosclerosis and impaired blood vessels

Thick blood to cause or prevent strokes and heart attacks proved by scientists

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Endologix publishes abdominal aortic aneurysm treatment trial results online

Kensey Nash announces financial results for fourth-quarter and full fiscal year 2009

Massachusetts General Hospital selects BDV's video and audio solution for improving operating room efficiency

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Researcher of LA BioMed elected to distinguished fellow status of SVS

Cardiovascular Systems' revenues in fourth-quarter of 2009 increases to $15.7 million

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News